Spectral MD is a predictive analytics company, providing AI assessments on whether a wound will heal through its proprietary DeepView platform. The company primarily operates in the United States and has a growing presence in Europe. It is listed on London’s AIM market and is capitalised at £44m.
In this interview, Spectral MD’s vice president of marketing and commercialisation, Christine Marks, discusses the value DeepView provides for quickly and accurately diagnosing the healing and non-healing areas of a wound. Spectral MD will go to market, first in assessing diabetic foot ulcers and then in burn application. Christine elaborates on the market opportunity from being the only specialist AI company in these areas. She also describes the company’s key growth drivers and the investments being made to support Spectral MD’s long-term growth.